CU20150051A7 - Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina - Google Patents

Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina

Info

Publication number
CU20150051A7
CU20150051A7 CUP2015000051A CU20150051A CU20150051A7 CU 20150051 A7 CU20150051 A7 CU 20150051A7 CU P2015000051 A CUP2015000051 A CU P2015000051A CU 20150051 A CU20150051 A CU 20150051A CU 20150051 A7 CU20150051 A7 CU 20150051A7
Authority
CU
Cuba
Prior art keywords
formula
compound
give
solvent
space
Prior art date
Application number
CUP2015000051A
Other languages
English (en)
Inventor
Ulrich Lücking
Dr Niels Böhnke
Dr Arne Scholz
Dr Philip Lienau
Dr Gerhard Siemeister
Dr Ulf Bömer
Dr Dirk Kosemund
Rolf Bohlmann
Dr Ludwing Zorn
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20150051A7 publication Critical patent/CU20150051A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se relaciona con derivados de N-(piridin-2-il)pirimidin-4-amina disustituida que contienen un grupo sulfoximina y que presentan la fórmula general (I), (ESPACIO PARA LA FÓRMULA) donde R1, R2, R3, R4 y R5 son como se definen en las reivindicaciones, que son útiles como medicamentos para el tratamiento y/o la profilaxis de los trastornos hiperproliferativos, enfermedades infecciosas inducidas por virus y/o de las enfermedades cardiovasculares. Adicionalmente, la invención se refiere a compuestos intermediarios de fórmulas (5) y (6), útiles para preparar los compuestos de fórmula (I) (ESPACIO PARA LAS FÓRMULAS) donde R1, R2, R3, R4 y R5 son como se definen en las reivindicaciones, y a procedimientos para la preparación de dichos compuestos de fórmula (I) o los solvatos, sales y/o solvatos de las sales de los mismos, en donde se hace reaccionar un compuesto de fórmula (5), con trifluoroacetamida y 1,3-dibromo-5,5-dimetilhidantoína en presencia de una sal alcalina de tert-butanol en un éter cíclico como solvente, para dar un compuesto de fórmula (6); o alternativamente se oxida un compuesto de fórmula (6), con una sal alcalina de ácido permangánico a una cetona alifática de fórmula C1-C2-C(O)-C1-C2-alquilo como solvente, seguido por la eliminación de dicho grupo trifluoroacetilo si está presente, para dar un compuesto de fórmula (I), en donde R5 es hidrógeno, (ESPACIO PARA LA FÓRMULA) o alternativamente, se oxida un compuesto de fórmula (6) con un oxidante a base de peroxomonosulfato en un solvente que se elige de un alcohol alifático de fórmula C1-C3-alquil-OH, agua y N,N-dimetilformamida, o una mezcla de los mismos, para dar un compuesto de fórmula (I), en donde R5 es hidrógeno.
CUP2015000051A 2012-11-15 2015-05-15 Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina CU20150051A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12192855 2012-11-15
PCT/EP2013/073683 WO2014076111A1 (en) 2012-11-15 2013-11-13 N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group

Publications (1)

Publication Number Publication Date
CU20150051A7 true CU20150051A7 (es) 2015-11-27

Family

ID=47148673

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000051A CU20150051A7 (es) 2012-11-15 2015-05-15 Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina

Country Status (26)

Country Link
US (1) US9650361B2 (es)
EP (1) EP2920164B1 (es)
JP (1) JP6263194B2 (es)
KR (1) KR20150082604A (es)
CN (1) CN104918932B (es)
AP (1) AP2015008436A0 (es)
AR (1) AR093503A1 (es)
AU (1) AU2013346866A1 (es)
BR (1) BR112015010484A2 (es)
CA (1) CA2891361C (es)
CL (1) CL2015001319A1 (es)
CR (1) CR20150257A (es)
CU (1) CU20150051A7 (es)
DO (1) DOP2015000117A (es)
EA (1) EA201590892A1 (es)
ES (1) ES2622566T3 (es)
IL (1) IL238370A0 (es)
MA (1) MA38091B1 (es)
MX (1) MX2015006171A (es)
PE (1) PE20151142A1 (es)
PH (1) PH12015501076A1 (es)
SG (1) SG11201503274WA (es)
TN (1) TN2015000186A1 (es)
TW (1) TW201418243A (es)
UY (1) UY35138A (es)
WO (1) WO2014076111A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
ES2616441T3 (es) * 2012-10-18 2017-06-13 Bayer Pharma Aktiengesellschaft Derivados de N-(piridin-2-il))pirimidin-4-amina que contienen un grupo sulfona
CN107001341B (zh) * 2014-10-16 2020-08-07 拜耳医药股份有限公司 含有磺亚胺基的氟化苯并呋喃基-嘧啶衍生物
CA2964683A1 (en) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
JP6847099B2 (ja) 2015-09-29 2021-03-24 バイエル ファーマ アクチエンゲゼルシャフト 新規な大環状スルホンジイミン化合物
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
US11440899B2 (en) * 2017-10-17 2022-09-13 Merck Patent Gmbh Pyrimidine TBK/IKKe inhibitor compounds and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1307271A (en) 1970-06-25 1973-02-14 Shell Int Research Sulphoximine derivatives and their use in herbicidal compositions
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2003037346A1 (en) 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
CA2515132C (en) 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7465805B2 (en) 2004-10-05 2008-12-16 Syngenta Limited Isoxazoline derivatives and their use as herbicides
US20090099160A1 (en) 2004-12-17 2009-04-16 David Andrews 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
EP2094681A1 (en) 2006-12-22 2009-09-02 Novartis AG Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
ES2539518T3 (es) 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
WO2008132138A1 (en) * 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
KR20120049940A (ko) 2009-09-04 2012-05-17 노파르티스 아게 키나제 억제제로서의 헤테로아릴 화합물
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
KR20120114224A (ko) 2009-10-12 2012-10-16 마이렉시스 인코포레이티드 Ｉｋｋ 엡실론 및/또는 ｔｂｋ１의 억제제로서의 아미노-피리미딘 화합물
CA2789200C (en) 2010-03-22 2020-05-26 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
DE102010046720A1 (de) 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
CA2816679A1 (en) 2010-11-17 2012-05-24 Novartis Ag 3-(aminoaryl)-pyridine compounds
WO2012101062A1 (en) 2011-01-28 2012-08-02 Novartis Ag Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
JP5947818B2 (ja) 2011-03-02 2016-07-06 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
WO2012117048A1 (en) 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
KR20140048873A (ko) 2011-04-12 2014-04-24 알츠하이머즈 인스티튜트 오브 아메리카, 인크. Ｉｋｋ－관련 키나제 엡실론 및 ｔａｎｋ 결합 키나제 1 억제제의 조성물 및 치료학적 용도
CN102731413A (zh) 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
AU2012244745A1 (en) 2011-04-19 2013-09-19 Bayer Intellectual Property Gmbh Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
CN103930399B (zh) * 2011-09-16 2016-03-16 拜耳知识产权有限责任公司 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物
CN103917527B (zh) 2011-09-16 2017-05-31 拜耳知识产权有限责任公司 二取代的5‑氟‑嘧啶
ES2616441T3 (es) * 2012-10-18 2017-06-13 Bayer Pharma Aktiengesellschaft Derivados de N-(piridin-2-il))pirimidin-4-amina que contienen un grupo sulfona
CN105102434A (zh) 2012-10-18 2015-11-25 拜耳药业股份公司 含砜基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺
WO2014076028A1 (en) 2012-11-15 2014-05-22 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group
ME02880B (me) 2012-11-15 2018-04-20 Bayer Pharma AG Derivati 5-fluoro- n- (piridin -2-il}piridi n- 2 - amina koji sadrze sulfoksiminsku grupu
EP3016945B1 (en) 2013-07-04 2017-05-03 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

Also Published As

Publication number Publication date
KR20150082604A (ko) 2015-07-15
WO2014076111A1 (en) 2014-05-22
BR112015010484A2 (pt) 2017-07-11
AP2015008436A0 (en) 2015-05-31
CR20150257A (es) 2015-07-01
US9650361B2 (en) 2017-05-16
EP2920164B1 (en) 2017-02-01
TW201418243A (zh) 2014-05-16
MX2015006171A (es) 2015-08-10
MA38091A3 (fr) 2017-03-31
CA2891361A1 (en) 2014-05-22
SG11201503274WA (en) 2015-06-29
EA201590892A1 (ru) 2015-11-30
UY35138A (es) 2014-06-30
AU2013346866A1 (en) 2015-05-21
MA38091B1 (fr) 2018-05-31
DOP2015000117A (es) 2015-06-15
IL238370A0 (en) 2015-06-30
CL2015001319A1 (es) 2015-07-17
EP2920164A1 (en) 2015-09-23
US20150291559A1 (en) 2015-10-15
JP2016501194A (ja) 2016-01-18
CN104918932A (zh) 2015-09-16
HK1215027A1 (zh) 2016-08-12
TN2015000186A1 (en) 2016-10-03
ES2622566T3 (es) 2017-07-06
MA38091A2 (fr) 2016-10-31
CA2891361C (en) 2021-07-20
PH12015501076A1 (en) 2015-08-03
AR093503A1 (es) 2015-06-10
CN104918932B (zh) 2017-07-18
JP6263194B2 (ja) 2018-01-17
PE20151142A1 (es) 2015-08-23

Similar Documents

Publication Publication Date Title
AR118124A2 (es) Proceso para la preparación de un inhibidor de pde4
BR112014008196B8 (pt) processo para a preparação de um composto da fórmula (i)
CL2015001304A1 (es) Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
AR086474A1 (es) Compuestos de pirazol pesticidas
CR20200540A (es) DERIVADOS DE AMINA PARA EL CONTROL DE PLAGAS (Divisional 2019-0244)
CO6811860A2 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
BR112013007610A8 (pt) Benzoxazinonas, composições herbicidas, processo para preparar composições herbicidas ativas e método para controlar vegetação indesejada
DOP2013000088A (es) Barra de refuerzo y método para fabricar la misma
AR075158A1 (es) Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos.
BR112014011930A2 (pt) método para a produção de alcano diol
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
UY35139A (es) 4- (orto) -fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina
PE20150877A1 (es) Composicion herbicida que tiene actividad herbicida mejorada
CO2018010787A2 (es) Compuesto de griseofulvina
BR112014029551A2 (pt) compostos de ácido dimetil-benzoico
PE20141201A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
CL2015001319A1 (es) Compuestos derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
BR112013028486A2 (pt) método para promover crescimento de planta
AR081908A1 (es) N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas
ECSP088257A (es) Derivados de amida
BR112013016637A2 (pt) processo para a preparação de derivados de 3-alquil-sulfinilbenzoíla
JP2018536647A5 (es)
PE20141391A1 (es) Combinacion que comprende un compuesto con actividad antiviral y un agente terapeutico
AR066242A1 (es) Tia(di)azoles como antagonistas del recpetor de dopamina 2 de disociacion rapida